Lakefront Biotherapeutics American Depositary Shares
LKFT
88 hedge funds and large institutions have $804M invested in Lakefront Biotherapeutics American Depositary Shares in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 35 increasing their positions, 17 reducing their positions, and 5 closing their positions.
320% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 5
106% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 17
41% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $7.36M
22% more funds holding
Funds holding: 72 → 88 (+16)
21% more capital invested
Capital invested by funds: $662M → $804M (+$142M)
0.94% more ownership
Funds ownership: 29.09% → 30.03% (+0.94%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$22.9M |
| 2 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
+$5.03M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$3.57M |
| 4 |
Morgan Stanley
New York
|
+$3.24M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$2.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$19.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.64M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.09M |
| 5 |
NM
Newtyn Management
New York
|
-$2.09M |
LKFT Hedge Fund Activity: Q4 2023 in Review
88 of the 6,871 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q4 2023, worth a combined $804M — up 21% from $662M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new LKFT positions and 5 closed out — a net gain of 16 holders — while 35 added to existing stakes and 17 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $22.9M. The largest seller was Stonepine Capital Management, cutting an estimated $19.9M.
- 88 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q4 2023, up from 72 in Q3 2023.
- Funds reported $804M of Lakefront Biotherapeutics American Depositary Shares stock for Q4 2023, up 21% quarter-over-quarter.
- 21 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q4 2023 and 5 closed out, a net change of +16 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q4 2023 was Deerfield Management, an estimated $22.9M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q4 2023 was Stonepine Capital Management, an estimated $19.9M sold.
Based on aggregated 13F filings for Q4 2023.